Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives DOI Creative Commons
Yang Zhang, Yifan Bu, Rui Zhao

и другие.

Therapeutic Advances in Endocrinology and Metabolism, Год журнала: 2024, Номер 15

Опубликована: Янв. 1, 2024

The term metabolic-associated fatty liver disease (MAFLD), with a global prevalence estimated at 38.77%, has gradually replaced the traditional concept of non-alcoholic (NAFLD). Compared to general population, incidence MAFLD is notably higher among pregnant women, posing potential risks both maternal and neonatal health. This review summarizes latest research on MAFLD, focusing its association pregnancy complications. Additionally, it provides comparative analysis previous studies NAFLD, presenting comprehensive perspective for clinical management. Findings suggest that women face risk gestational hypertension cesarean delivery compared those while diabetes mellitus remains similar between two conditions. associated an increased likelihood delivering large-for-gestational-age infants heightened preterm birth low weight. Current treatment strategies focus lifestyle modifications, such as dietary adjustments physical activity. However, there urgent need development safe effective pharmacological treatments, particularly tailored toward women. Future should delve deeper into causal relationships complications explore optimal therapeutic approaches improve outcomes mothers their infants.

Язык: Английский

Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up DOI
Hun Jee Choe, Joon Ho Moon, Won Kim

и другие.

Metabolism, Год журнала: 2024, Номер unknown, С. 155800 - 155800

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

29
MAFLD as part of systemic metabolic dysregulation DOI
Jing Zhao, Lu Liu,

Yingying Cao

и другие.

Hepatology International, Год журнала: 2024, Номер 18(S2), С. 834 - 847

Опубликована: Апрель 9, 2024

Язык: Английский

Процитировано

16
Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus and associated hepatic steatosis DOI Creative Commons
Youngae Jung, Seung Mi Lee,

Jinhaeng Lee

и другие.

Cardiovascular Diabetology, Год журнала: 2025, Номер 24(1)

Опубликована: Март 20, 2025

Abstract Background This study aims to identify early metabolomic biomarkers of gestational diabetes mellitus (GDM) and evaluate their association with hepatic steatosis. Methods We compared maternal serum profiles between women who developed GDM ( n = 118) matched controls during the first (10–14 weeks) second (24–28 trimesters using ultra-performance liquid chromatography coupled mass spectrometry. Mediation analysis was performed mediating role metabolic dysfunction-associated steatotic liver disease (MASLD) in relationship metabolites subsequent development GDM. A refined prediction model predict established clinical factors selected metabolites. Results Significant alterations circulating metabolites, including amino acids, bile phospholipids, were observed group pregnancy. revealed that several glycocholic acid (proportion mediated (PM) 31.9%), butanoyl carnitine (PM 25.7%), uric 22.4%), had significant indirect effects on incidence by The composed trimester demonstrated higher performance predicting than solely (AUC, 0.85 vs. 0.63, p < 0.001). Conclusions Women exhibited altered from pregnancy, which showed a correlation GDM, MASLD as mediator. Selected may serve predictive markers potential targets for risk assessment intervention Graphical abstract Research insights What is currently known about this topic? Gestational common pregnancy complication health risks. Early identification at high crucial timely improved outcomes. key research question? are associated development? Does mediate specific risk? new? phosphatidylethanolamines, phosphatidylinositols sera later significantly risk, mediation proportions ranging 9.7 31.9%. development. How might influence practice? These results provide new into highlight MASLD. comprehensive approach contribute models targeted interventions prevention.

Язык: Английский

Процитировано

0
The Maternal and Fetal Consequences of Metabolic Dysfunction-Associated Fatty Liver Disease and Gestational Diabetes Mellitus DOI Open Access
Thora Y. Chai, Jacob George, Dharmintra Pasupathy

и другие.

Nutrients, Год журнала: 2025, Номер 17(10), С. 1730 - 1730

Опубликована: Май 20, 2025

Both metabolic dysfunction-associated fatty liver disease (MAFLD) and gestational diabetes mellitus (GDM) during pregnancy are emerging as an adverse synergistic relationship of growing concern. This narrative review focuses on the maternal fetal consequences associated with women who have MAFLD and/or GDM pregnancy, including exploration long-term cardiometabolic risks for postpartum childhood health. We conclude that implementation a life course approach to management these high-risk remains paramount.

Язык: Английский

Процитировано

0
Metabolic dysfunction–associated steatotic liver disease: Emerging risk factors for adverse pregnancy outcomes DOI Open Access
Georgia Sofia Karachaliou, Ayako Suzuki

Clinical Liver Disease, Год журнала: 2024, Номер 23(1)

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

3
The Role of Helicobacter pylori and Metabolic Syndrome-Related Mast Cell Activation Pathologies and Their Potential Impact on Pregnancy and Neonatal Outcomes DOI Open Access
Maria Tzitiridou‐Chatzopoulou, Evangelos Kazakos, Eirini Orovou

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(8), С. 2360 - 2360

Опубликована: Апрель 18, 2024

Helicobacter pylori infection, a significant global burden beyond the gastrointestinal tract, has long been implicated in various systemic pathologies. Rising evidence suggests that bacterium's intricate relationship with immune system and its potential to induce chronic inflammation impact diverse pathophysiological processes pregnant women may turn affect incidence of several adverse pregnancy neonate outcomes. which linked metabolic syndrome other disorders by provoking pericyte dysfunction, hyperhomocysteinemia, galectin-3, atrial fibrillation, gut dysbiosis, mast cell activation pathologies, also contribute neonatal Together increasing our biological understanding individual collective involvement infection-related concurrent cells maternal, fetus, health outcomes, present narrative review foster related research endeavors offer novel therapeutic approaches informed clinical practice interventions mitigate relevant risks this critical topic among their offspring.

Язык: Английский

Процитировано

2
Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study DOI Creative Commons
Young Mi Jung, Seung Mi Lee, Wonyoung Wi

и другие.

JHEP Reports, Год журнала: 2024, Номер 6(4), С. 101033 - 101033

Опубликована: Фев. 23, 2024

Background and AimsAdverse pregnancy outcomes (APOs) can worsen cardiometabolic risk factors in women, raising their likelihood of developing diseases at a young age after initial pregnancy. Nevertheless, there is limited data on the newly metabolic dysfunction-associated steatotic liver disease (MASLD) women who have had APOs. This study aimed to evaluate new-onset MASLD experiencing APOs.MethodsSingleton pregnant underwent national health screenings one year before delivery were included this study. APOs defined as presence least followings: hypertensive disorders (HDP), gestational diabetes mellitus (GDM), preterm birth, low birth weight, placental abruption. The primary outcome was based APOs.ResultsAmong 80,037 participants, 9,320 (11.6%) experienced during Women an increased even adjustments for various covariates (adjusted OR, 1.58; 95% CI, 1.45–1.72). In particular, either HDP or GDM showed significantly (aOR, 2.20; 1.81–2.67 aOR, 1.83; 1.65–2.03 GDM). Moreover, tendency toward according number (P<0.001 trend odds).ConclusionsAPOs associated with delivery. Specifically, only identified MASLD.Impact implicationsThis nationwide cohort confirms that postpartum history adverse are (MASLD). These findings may bring us step closer understanding exact mechanisms underlying such important association between prior cardiovascular (CVD) among women. bidirectional highlights importance considering assessing CVD It suggests need monitoring lifestyle interventions reduce subsequent complications.

Язык: Английский

Процитировано

2
Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea DOI
Min Gu Kang, Chang Hun Lee, Chen Shen

и другие.

Journal of Hepatology, Год журнала: 2023, Номер 80(5), С. e216 - e218

Опубликована: Окт. 11, 2023

Язык: Английский

Процитировано

5
Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Lucy C. Taylor, Gertrude Arthur, Miguel Cruz

и другие.

International Journal of Translational Medicine, Год журнала: 2024, Номер 4(4), С. 782 - 809

Опубликована: Дек. 9, 2024

Sex differences are a complex and crucial variable in developing progressing metabolic cardiovascular disease pathophysiology clinical outcomes. The female sex, compared to the male is protected from disturbances their resulting events. However, peculiar life phases associated with females, such as puberty, pregnancy, premenopausal menopausal stages, all different risks for development of (CVD). Metabolic dysfunction-associated steatotic liver (MASLD), condition hepatic steatosis, at least one feature syndrome an increased risk MASLD its progression CVD differs between men women. Differences several factors, including formyl peptide receptor (FPR) 2, adipose tissue distribution, pyruvate kinase (LPK), ketone body production, may underlie sex MASLD-induced CVD. Understanding specific factors involved sexes crucial. This knowledge will provide important insights into mechanisms responsible complications can potentially lead therapeutics targeted explicitly each offering new hope fight against

Язык: Английский

Процитировано

1
Maternal sterol 27-hydroxylase is crucial for securing fetal development DOI Open Access
Mitsuyoshi Suzuki,

Satoshi Nakano,

Natsumi Miharada

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Ноя. 12, 2023

Summary The maternal body helps in providing nutrients and degrading toxic metabolites instead of the fetal body; disruptions these mechanisms affect normal development. Sterol 27-hydroxylase ( Cyp27a1 ) is involved alternative pathway bile acid synthesis, which enhanced during pregnancy. However, its role development remains unclear. Here, we demonstrate that activity essential for progression pregnancy organ formation. Depletion reduced rate litter size. Newborn mice died respiratory distress syndrome resulting from absence mature alveolar epithelial cells. These phenotypes were caused by 7α-hydroxycholesterol (7α-HC) accumulating -deficient mice. Mechanistically, 7α-HC destabilized Fau protein, mediating ribosome assembly, downregulation poor polysome formation, lower protein impaired lung maturation. Overall, this study revealed an mechanism securing a metabolite body.

Язык: Английский

Процитировано

1